ANI Pharmaceuticals, Inc. (ANIP)
Nasdaq: ANIP · Pharmaceutical Preparations · Baudette, MN · filing with the SEC since 1999
Grade6.3
◀ Past 6.3● Present 6.6▶ Future 5.8
Who owns ANI Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
1
Blackrock, Inc. holds 12.8% of Common Stock, as its SCHEDULE 13G/A filed Jul 27, 2026 says.
Directors and officers
16
report now, of 27 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 27, 2026 · Common Stock · 11.3% in Oct 17, 2025
Robert E. Brown, Jr.
SCHEDULE 13D/A · filed Aug 22, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.4% in Mar 13, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Apr 10, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.2% in Jan 21, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.2% in Jun 4, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What ANIP reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Alimera Sciences, Inc
A company bought · acquisition · Sep 2024 · owns, named in the 10-K filed Feb 27, 2026
Alimera
A company bought · acquisition · owns, named in the 10-K filed Feb 27, 2026
Alvogen Inc
A company bought · asset acquisition · owns, named in the 10-K filed Feb 27, 2026
Novitium
A company bought · acquisition · owns, named in the 10-K filed Feb 27, 2026
11 subsidiaries in 6 countries, from the list filed with the 10-K filed Feb 27, 2026.
Insider tradesForm 4
50sales
0purchases
35sales on a scheduled plan
12people selling
$15.7Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 30, 2025 to Oct 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 30 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Lalwani Nikhil | PRESIDENT & CEO | 4 | $5.4M | 3 | 0 | $0 |
| Walsh Patrick D | CHAIRMAN, INTERIM PRES. & CEO | 4 | $2.3M | 0 | 0 | $0 |
| Carey Stephen P. | SVP & CFO | 9 | $2.2M | 7 | 0 | $0 |
| Mutz Christopher | HEAD OF RARE DISEASE | 6 | $1.6M | 6 | 0 | $0 |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 2 | $1.3M | 0 | 0 | $0 |
| Davis Krista | SVP, CHIEF HR OFFICER | 5 | $900,000 | 5 | 0 | $0 |
| Gutwerg Ori | SVP, GENERICS | 3 | $600,000 | 0 | 0 | $0 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 12 | $500,000 | 12 | 0 | $0 |
| Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | 2 | $400,000 | 0 | 0 | $0 |
| Haughey Thomas | director | 1 | $200,000 | 1 | 0 | $0 |
| Thoma Jeanne | director | 1 | $100,000 | 1 | 0 | $0 |
| Tannenbaum Renee P | director | 1 | $100,000 | 0 | 0 | $0 |